Dyadic International (NASDAQ:DYAI) Share Price Crosses Above 50-Day Moving Average – Should You Sell?

Dyadic International Inc. (NASDAQ:DYAI) crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.87 and traded as high as $1.60. Dyadic International shares last traded at $1.30, with a volume of 337,923 shares traded.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday, June 24th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Dyadic International presently has a consensus rating of “Hold” and a consensus target price of $3.00.

Dyadic International Price Performance

The stock has a market cap of $47.37 million, a price-to-earnings ratio of -5.65 and a beta of 1.15. The stock’s 50 day moving average price is $0.87 and its two-hundred day moving average price is $0.85. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08.

Dyadic International (NASDAQ:DYAI) last issued its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The company had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%. Equities research analysts forecast that Dyadic International Inc. will post 0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Dyadic International

Several hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC grew its stake in shares of Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares during the period. Landscape Capital Management L.L.C. acquired a new position in shares of Dyadic International in the 3rd quarter valued at $190,000. Bank of America Corp DE lifted its stake in shares of Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the period. Finally, Marathon Capital Management boosted its holdings in Dyadic International by 142.9% during the fourth quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock worth $80,000 after buying an additional 50,000 shares in the last quarter. Hedge funds and other institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.